Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 11/20 | 0.39 |
| ▸ | GIPR | P48546 | 9/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13653122 | 0.93 | GCGR (0.37) | GCGRGIPRHDAC1MEN1KMT2A | |
| SCHEMBL13653112 | 0.88 | GCGR (0.40) | GCGRGIPRHDAC1MEN1KMT2A | |
| SCHEMBL13653127 | 0.86 | KDM1A (0.40) | GCGRGIPRMEN1KMT2AKDM1A | |
| SCHEMBL13653115 | 0.85 | APEX1 (0.41) | GCGRGIPRMEN1KMT2ATP53 | |
| SCHEMBL4189862 | 0.84 | HDAC1 (0.46) | HDAC1KDM1A | |
| SCHEMBL13653109 | 0.81 | PDE4A (0.39) | HDAC1MEN1KMT2ARXFP1 | |
| SCHEMBL4189530 | 0.81 | KMT2A (0.41) | GCGRGIPRMEN1KMT2ATP53 | |
| SCHEMBL13653102 | 0.81 | MEN1 (0.42) | HDAC1MEN1KMT2ARXFP1 | |
| SCHEMBL4185804 | 0.80 | PDE4A (0.44) | MEN1KMT2ARXFP1 | |
| SCHEMBL13653136 | 0.78 | CA12 (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | GCGR 3989/4885GIPR 869/4885HDAC1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.